25 XP   0   0   10

Lipocine Inc
Buy, Hold or Sell?

Let's analyse Lipocine together

PenkeI guess you are interested in Lipocine Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lipocine Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Lipocine Inc

I send you an email if I find something interesting about Lipocine Inc.

Quick analysis of Lipocine (30 sec.)










What can you expect buying and holding a share of Lipocine? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$3.83
Expected worth in 1 year
$7.26
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$3.43
Return On Investment
66.9%

For what price can you sell your share?

Current Price per Share
$5.13
Expected price per share
$3.18 - $5.3873
How sure are you?
50%

1. Valuation of Lipocine (5 min.)




Live pricePrice per Share (EOD)

$5.13

Intrinsic Value Per Share

$-31.43 - $-14.77

Total Value Per Share

$-27.60 - $-10.94

2. Growth of Lipocine (5 min.)




Is Lipocine growing?

Current yearPrevious yearGrowGrow %
How rich?$20.3m$38.8m-$13m-50.5%

How much money is Lipocine making?

Current yearPrevious yearGrowGrow %
Making money-$4m-$2.4m-$1.6m-40.7%
Net Profit Margin-2,743.7%-92.7%--

How much money comes from the company's main activities?

3. Financial Health of Lipocine (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#598 / 1031

Most Revenue
#1028 / 1031

Most Profit
#427 / 1031

Most Efficient
#884 / 1031

What can you expect buying and holding a share of Lipocine? (5 min.)

Welcome investor! Lipocine's management wants to use your money to grow the business. In return you get a share of Lipocine.

What can you expect buying and holding a share of Lipocine?

First you should know what it really means to hold a share of Lipocine. And how you can make/lose money.

Speculation

The Price per Share of Lipocine is $5.1288. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lipocine.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lipocine, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.83. Based on the TTM, the Book Value Change Per Share is $0.86 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lipocine.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.43-8.4%-0.77-15.0%-0.03-0.6%-0.53-10.4%-0.62-12.1%
Usd Book Value Change Per Share-0.40-7.7%0.8616.7%-0.03-0.6%0.173.3%0.010.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.40-7.7%0.8616.7%-0.03-0.6%0.173.3%0.010.2%
Usd Price Per Share2.79-2.78-0.75-1.56-3.46-
Price to Earnings Ratio-1.62--1.05--5.89--1.86--2.21-
Price-to-Total Gains Ratio-7.02--4.36--24.76--6.13--2.41-
Price to Book Ratio0.73-0.61-1.67-1.27-1.43-
Price-to-Total Gains Ratio-7.02--4.36--24.76--6.13--2.41-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.1288
Number of shares194
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.860.17
Usd Total Gains Per Share0.860.17
Gains per Quarter (194 shares)166.4033.26
Gains per Year (194 shares)665.59133.02
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
106666560133123
20133113220266256
30199719880399389
40266226540532522
50332833200665655
60399439860798788
70465946520931921
8053255318010641054
9059905984011971187
10066566650013301320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%1.047.01.02.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%13.027.00.032.5%15.034.00.030.6%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.039.02.5%1.00.048.02.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%13.027.00.032.5%15.034.00.030.6%

Fundamentals of Lipocine

About Lipocine Inc

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

Fundamental data was last updated by Penke on 2024-03-20 22:56:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Lipocine Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Lipocine earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Lipocine to the Biotechnology industry mean.
  • A Net Profit Margin of -4,149.8% means that $-41.50 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lipocine Inc:

  • The MRQ is -4,149.8%. The company is making a huge loss. -2
  • The TTM is -2,743.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-4,149.8%TTM-2,743.7%-1,406.1%
TTM-2,743.7%YOY-92.7%-2,651.0%
TTM-2,743.7%5Y-1,529,683.8%+1,526,940.1%
5Y-1,529,683.8%10Y-765,037.9%-764,645.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,149.8%-171.8%-3,978.0%
TTM-2,743.7%-205.8%-2,537.9%
YOY-92.7%-262.1%+169.4%
5Y-1,529,683.8%-455.6%-1,529,228.2%
10Y-765,037.9%-589.0%-764,448.9%
1.1.2. Return on Assets

Shows how efficient Lipocine is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lipocine to the Biotechnology industry mean.
  • -9.9% Return on Assets means that Lipocine generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lipocine Inc:

  • The MRQ is -9.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.9%TTM-15.0%+5.0%
TTM-15.0%YOY-5.8%-9.2%
TTM-15.0%5Y-12.2%-2.8%
5Y-12.2%10Y-13.2%+1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.9%-12.5%+2.6%
TTM-15.0%-12.2%-2.8%
YOY-5.8%-11.2%+5.4%
5Y-12.2%-13.4%+1.2%
10Y-13.2%-14.7%+1.5%
1.1.3. Return on Equity

Shows how efficient Lipocine is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lipocine to the Biotechnology industry mean.
  • -11.2% Return on Equity means Lipocine generated $-0.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lipocine Inc:

  • The MRQ is -11.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.2%TTM-16.3%+5.1%
TTM-16.3%YOY-6.2%-10.1%
TTM-16.3%5Y-22.4%+6.1%
5Y-22.4%10Y-20.1%-2.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.2%-15.8%+4.6%
TTM-16.3%-15.7%-0.6%
YOY-6.2%-13.9%+7.7%
5Y-22.4%-18.3%-4.1%
10Y-20.1%-19.2%-0.9%

1.2. Operating Efficiency of Lipocine Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Lipocine is operating .

  • Measures how much profit Lipocine makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lipocine to the Biotechnology industry mean.
  • An Operating Margin of -5,008.5% means the company generated $-50.09  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lipocine Inc:

  • The MRQ is -5,008.5%. The company is operating very inefficient. -2
  • The TTM is -3,170.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-5,008.5%TTM-3,170.7%-1,837.9%
TTM-3,170.7%YOY-183.1%-2,987.6%
TTM-3,170.7%5Y-672,444.7%+669,274.0%
5Y-672,444.7%10Y-336,417.3%-336,027.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5,008.5%-299.1%-4,709.4%
TTM-3,170.7%-210.1%-2,960.6%
YOY-183.1%-279.7%+96.6%
5Y-672,444.7%-459.9%-671,984.8%
10Y-336,417.3%-596.9%-335,820.4%
1.2.2. Operating Ratio

Measures how efficient Lipocine is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 51.09 means that the operating costs are $51.09 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lipocine Inc:

  • The MRQ is 51.085. The company is inefficient in keeping operating costs low. -1
  • The TTM is 32.204. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ51.085TTM32.204+18.881
TTM32.204YOY2.081+30.123
TTM32.2045Y6,724.776-6,692.572
5Y6,724.77610Y3,364.377+3,360.400
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ51.0852.861+48.224
TTM32.2043.193+29.011
YOY2.0813.615-1.534
5Y6,724.7765.560+6,719.216
10Y3,364.3777.396+3,356.981

1.3. Liquidity of Lipocine Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Lipocine is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.69 means the company has $8.69 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lipocine Inc:

  • The MRQ is 8.687. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.588. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.687TTM12.588-3.901
TTM12.588YOY19.705-7.116
TTM12.5885Y9.672+2.916
5Y9.67210Y11.992-2.320
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.6873.986+4.701
TTM12.5884.440+8.148
YOY19.7055.552+14.153
5Y9.6726.158+3.514
10Y11.9926.492+5.500
1.3.2. Quick Ratio

Measures if Lipocine is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lipocine to the Biotechnology industry mean.
  • A Quick Ratio of 14.95 means the company can pay off $14.95 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lipocine Inc:

  • The MRQ is 14.953. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 22.018. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.953TTM22.018-7.065
TTM22.018YOY36.126-14.108
TTM22.0185Y15.906+6.112
5Y15.90610Y17.491-1.586
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.9533.638+11.315
TTM22.0184.168+17.850
YOY36.1265.515+30.611
5Y15.9066.012+9.894
10Y17.4916.209+11.282

1.4. Solvency of Lipocine Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Lipocine assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lipocine to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Lipocine assets are financed with 11.4% credit (debt) and the remaining percentage (100% - 11.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lipocine Inc:

  • The MRQ is 0.114. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.083. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.114TTM0.083+0.032
TTM0.083YOY0.065+0.018
TTM0.0835Y0.273-0.190
5Y0.27310Y0.215+0.057
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1140.335-0.221
TTM0.0830.330-0.247
YOY0.0650.267-0.202
5Y0.2730.367-0.094
10Y0.2150.378-0.163
1.4.2. Debt to Equity Ratio

Measures if Lipocine is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lipocine to the Biotechnology industry mean.
  • A Debt to Equity ratio of 12.9% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lipocine Inc:

  • The MRQ is 0.129. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.091. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.129TTM0.091+0.039
TTM0.091YOY0.070+0.020
TTM0.0915Y0.558-0.468
5Y0.55810Y0.410+0.149
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1290.376-0.247
TTM0.0910.398-0.307
YOY0.0700.334-0.264
5Y0.5580.429+0.129
10Y0.4100.476-0.066

2. Market Valuation of Lipocine Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Lipocine generates.

  • Above 15 is considered overpriced but always compare Lipocine to the Biotechnology industry mean.
  • A PE ratio of -1.62 means the investor is paying $-1.62 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lipocine Inc:

  • The EOD is -2.987. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.625. Based on the earnings, the company is expensive. -2
  • The TTM is -1.054. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.987MRQ-1.625-1.362
MRQ-1.625TTM-1.054-0.570
TTM-1.054YOY-5.888+4.834
TTM-1.0545Y-1.860+0.806
5Y-1.86010Y-2.213+0.353
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.987-2.643-0.344
MRQ-1.625-2.418+0.793
TTM-1.054-2.742+1.688
YOY-5.888-4.123-1.765
5Y-1.860-6.257+4.397
10Y-2.213-6.478+4.265
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lipocine Inc:

  • The EOD is -3.355. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.825. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.369. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.355MRQ-1.825-1.530
MRQ-1.825TTM-1.369-0.456
TTM-1.369YOY-5.304+3.935
TTM-1.3695Y-1.868+0.499
5Y-1.86810Y-2.570+0.703
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.355-3.244-0.111
MRQ-1.825-2.939+1.114
TTM-1.369-3.478+2.109
YOY-5.304-5.592+0.288
5Y-1.868-8.473+6.605
10Y-2.570-8.881+6.311
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Lipocine is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.73 means the investor is paying $0.73 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lipocine Inc:

  • The EOD is 1.338. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.728. Based on the equity, the company is cheap. +2
  • The TTM is 0.606. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.338MRQ0.728+0.610
MRQ0.728TTM0.606+0.122
TTM0.606YOY1.673-1.067
TTM0.6065Y1.266-0.660
5Y1.26610Y1.427-0.161
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.3382.124-0.786
MRQ0.7282.041-1.313
TTM0.6062.118-1.512
YOY1.6732.915-1.242
5Y1.2663.682-2.416
10Y1.4274.114-2.687
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lipocine Inc.

3.1. Institutions holding Lipocine Inc

Institutions are holding 9.167% of the shares of Lipocine Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc4.166022145900
2023-12-31BlackRock Inc1.40807484600
2023-12-31Susquehanna International Group, LLP1.064805660131272123.4632
2023-12-31Geode Capital Management, LLC0.91904885400
2023-12-31Two Sigma Advisers, LLC0.49330.000226222-30700-53.9335
2023-12-31Renaissance Technologies Corp0.35360.000118797320020.5168
2023-12-31State Street Corporation0.350401862600
2023-12-31WEALTH EFFECTS LLC0.27540.015414639-4122-21.9711
2023-12-31Tower Research Capital LLC0.04210.000122381984781.1024
2023-12-31Morgan Stanley - Brokerage Accounts0.0136072200
2023-12-31CALDWELL SUTTER CAPITAL INC0.00890.000747100
2023-12-31Royal Bank of Canada0.00170911418.1818
2023-12-31FMR Inc0.00170903152.5424
2023-12-31Advisor Group Holdings, Inc.0.001306800
2023-12-31Tidemark LLC0.00110.000159590
2023-12-31Group One Trading, LP0.00105200
2023-12-31Wells Fargo & Co0.000804125.1282
2023-12-31JPMorgan Chase & Co0.000209-174-95.082
2023-12-31Bank of America Corp0.000106-53-89.8305
2023-09-30Bridgeway Capital Management, LLC000-24665-100
Total 9.1030.0166483891-23152-4.8%

3.2. Funds holding Lipocine Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.6539014107600
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.39740.00037428300
2024-01-31Fidelity Extended Market Index0.52650.00032798900
2024-01-31Vifag 2002 SICAV0.33430.11761777000
2024-01-31Fidelity Total Market Index0.14290759500
2024-01-31Fidelity Series Total Market Index0.11260598500
2023-12-31BlackRock U.S. Equity Market F0.10870.00015780100.1733
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.09460.0002502800
2023-12-31T. Rowe Price U.S. Equities Tr0.0930.0002494200
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.082904409-136658-96.8745
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.08290.0001440900
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0760.0002403880.1985
2023-12-31NT Ext Equity Mkt Idx Fd - L0.07030.0002373800
2023-12-31Northern Trust Extended Eq Market Idx0.07030.0002373800
2024-01-31Fidelity Nasdaq Composite Index0.06780.0001360300
2024-01-31Schwab Total Stock Market Index0.05530.0001294200
2024-02-29Dimensional US Targeted Value ETF0.04930.0001262200
2024-01-31Spartan Total Market Index Pool E0.04210223900
2024-02-29Vanguard U.S. Eq Idx £ Acc0.03180169100
2024-01-31Spartan Extended Market Index Pool E0.02670.0003141900
Total 6.11930.12325296-136640-42.0%

3.3. Insider Transactions

Insiders are holding 3.034% of the shares of Lipocine Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-25Mahesh V PatelBUY87065.03
2023-03-24Mahesh V PatelBUY88235.44
2023-03-20Richard Dana OnoBUY2355.78

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Lipocine Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.3970.858-146%-0.029-93%0.171-332%0.008-5223%
Book Value Per Share--3.8324.861-21%0.438+774%2.751+39%3.607+6%
Current Ratio--8.68712.588-31%19.705-56%9.672-10%11.992-28%
Debt To Asset Ratio--0.1140.083+39%0.065+76%0.273-58%0.215-47%
Debt To Equity Ratio--0.1290.091+43%0.070+84%0.558-77%0.410-68%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Eps---0.429-0.769+79%-0.030-93%-0.531+24%-0.623+45%
Free Cash Flow Per Share---0.382-0.559+46%-0.034-91%-0.434+14%-0.541+42%
Free Cash Flow To Equity Per Share---0.383-0.540+41%-0.040-90%0.036-1177%0.054-813%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---14.770--------
Intrinsic Value_10Y_min---31.428--------
Intrinsic Value_1Y_max---1.582--------
Intrinsic Value_1Y_min---2.346--------
Intrinsic Value_3Y_max---4.677--------
Intrinsic Value_3Y_min---7.786--------
Intrinsic Value_5Y_max---7.677--------
Intrinsic Value_5Y_min---13.993--------
Market Cap27263828.904+46%14831165.70014788771.956+0%66893529.073-78%29695686.207-50%37469661.637-60%
Net Profit Margin---41.498-27.437-34%-0.927-98%-15296.838+36762%-7650.379+18336%
Operating Margin---50.085-31.707-37%-1.831-96%-6724.447+13326%-3364.173+6617%
Operating Ratio--51.08532.204+59%2.081+2355%6724.776-99%3364.377-98%
Pb Ratio1.338+46%0.7280.606+20%1.673-56%1.266-43%1.427-49%
Pe Ratio-2.987-84%-1.625-1.054-35%-5.888+262%-1.860+15%-2.213+36%
Price Per Share5.129+46%2.7902.782+0%0.755+270%1.555+79%3.461-19%
Price To Free Cash Flow Ratio-3.355-84%-1.825-1.369-25%-5.304+191%-1.868+2%-2.570+41%
Price To Total Gains Ratio-12.909-84%-7.022-4.359-38%-24.756+253%-6.134-13%-2.406-66%
Quick Ratio--14.95322.018-32%36.126-59%15.906-6%17.491-15%
Return On Assets---0.099-0.150+51%-0.058-42%-0.122+23%-0.132+33%
Return On Equity---0.112-0.163+46%-0.062-45%-0.224+100%-0.201+79%
Total Gains Per Share---0.3970.858-146%-0.029-93%0.171-332%0.008-5223%
Usd Book Value--20369443.00025840748.750-21%38895840.250-48%25057341.200-19%26525884.000-23%
Usd Book Value Change Per Share---0.3970.858-146%-0.029-93%0.171-332%0.008-5223%
Usd Book Value Per Share--3.8324.861-21%0.438+774%2.751+39%3.607+6%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Eps---0.429-0.769+79%-0.030-93%-0.531+24%-0.623+45%
Usd Free Cash Flow---2031471.000-2969789.250+46%-3034927.975+49%-2769974.345+36%-3379558.498+66%
Usd Free Cash Flow Per Share---0.382-0.559+46%-0.034-91%-0.434+14%-0.541+42%
Usd Free Cash Flow To Equity Per Share---0.383-0.540+41%-0.040-90%0.036-1177%0.054-813%
Usd Market Cap27263828.904+46%14831165.70014788771.956+0%66893529.073-78%29695686.207-50%37469661.637-60%
Usd Price Per Share5.129+46%2.7902.782+0%0.755+270%1.555+79%3.461-19%
Usd Profit---2282253.000-4088020.500+79%-2424729.000+6%-3032878.000+33%-3771325.125+65%
Usd Revenue--54997.000-753002.250+1469%2499222.000-98%9405786.964-99%11415292.057-100%
Usd Total Gains Per Share---0.3970.858-146%-0.029-93%0.171-332%0.008-5223%
 EOD+5 -3MRQTTM+16 -17YOY+7 -285Y+17 -1810Y+17 -18

4.2. Fundamental Score

Let's check the fundamental score of Lipocine Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.987
Price to Book Ratio (EOD)Between0-11.338
Net Profit Margin (MRQ)Greater than0-41.498
Operating Margin (MRQ)Greater than0-50.085
Quick Ratio (MRQ)Greater than114.953
Current Ratio (MRQ)Greater than18.687
Debt to Asset Ratio (MRQ)Less than10.114
Debt to Equity Ratio (MRQ)Less than10.129
Return on Equity (MRQ)Greater than0.15-0.112
Return on Assets (MRQ)Greater than0.05-0.099
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Lipocine Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5071.290
Ma 20Greater thanMa 504.153
Ma 50Greater thanMa 1004.015
Ma 100Greater thanMa 2003.373
OpenGreater thanClose4.950
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets23,001
Total Liabilities2,632
Total Stockholder Equity20,369
 As reported
Total Liabilities 2,632
Total Stockholder Equity+ 20,369
Total Assets = 23,001

Assets

Total Assets23,001
Total Current Assets22,861
Long-term Assets140
Total Current Assets
Cash And Cash Equivalents 4,772
Short-term Investments 17,264
Net Receivables 52
Other Current Assets 773
Total Current Assets  (as reported)22,861
Total Current Assets  (calculated)22,861
+/-0
Long-term Assets
Property Plant Equipment 116
Long-term Assets Other 24
Long-term Assets  (as reported)140
Long-term Assets  (calculated)140
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,632
Long-term Liabilities0
Total Stockholder Equity20,369
Total Current Liabilities
Short-term Debt 17
Accounts payable 1,396
Other Current Liabilities 1,218
Total Current Liabilities  (as reported)2,632
Total Current Liabilities  (calculated)2,632
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock9
Retained Earnings -199,777
Accumulated Other Comprehensive Income 7
Other Stockholders Equity 220,131
Total Stockholder Equity (as reported)20,369
Total Stockholder Equity (calculated)20,369
+/-0
Other
Capital Stock9
Cash and Short Term Investments 22,036
Common Stock Shares Outstanding 5,316
Liabilities and Stockholders Equity 23,001
Net Debt -4,755
Net Invested Capital 20,369
Net Working Capital 20,230
Property Plant and Equipment Gross 1,298
Short Long Term Debt Total 17



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
32
27
3
1
1
0
0
37,171
46,108
42,102
35,486
32,018
27,994
25,057
53,797
48,428
45,377
38,774
33,348
29,554
27,343
27,222
28,048
26,255
25,325
31,681
25,302
22,685
20,852
22,989
19,677
17,342
19,658
20,992
23,485
24,752
25,353
50,577
47,179
40,389
52,482
47,604
42,193
39,424
37,543
34,022
30,483
24,752
23,001
23,00124,75230,48334,02237,54339,42442,19347,60452,48240,38947,17950,57725,35324,75223,48520,99219,65817,34219,67722,98920,85222,68525,30231,68125,32526,25528,04827,22227,34329,55433,34838,77445,37748,42853,79725,05727,99432,01835,48642,10246,10837,171001132732
   > Total Current Assets 
32
27
3
1
1
0
0
37,091
46,034
42,029
35,437
31,953
27,896
24,951
44,150
42,289
44,878
38,642
33,197
29,412
27,209
27,095
27,928
26,142
25,219
31,625
25,251
22,638
20,809
22,950
19,642
17,311
19,631
20,965
23,460
24,727
25,329
45,944
47,156
40,365
46,380
43,498
38,080
36,111
34,135
30,615
27,085
24,614
22,861
22,86124,61427,08530,61534,13536,11138,08043,49846,38040,36547,15645,94425,32924,72723,46020,96519,63117,31119,64222,95020,80922,63825,25131,62525,21926,14227,92827,09527,20929,41233,19738,64244,87842,28944,15024,95127,89631,95335,43742,02946,03437,091001132732
       Cash And Cash Equivalents 
23
18
3
1
1
0
0
36,839
45,264
41,773
34,164
31,667
27,666
24,764
38,297
23,926
20,008
14,115
12,373
4,707
5,561
6,937
16,631
9,271
3,211
8,561
1,602
4,803
8,078
8,222
3,664
6,665
9,729
15,135
13,838
12,938
19,217
15,602
10,968
4,517
2,951
5,733
4,981
2,397
3,148
4,769
5,015
4,073
4,772
4,7724,0735,0154,7693,1482,3974,9815,7332,9514,51710,96815,60219,21712,93813,83815,1359,7296,6653,6648,2228,0784,8031,6028,5613,2119,27116,6316,9375,5614,70712,37314,11520,00823,92638,29724,76427,66631,66734,16441,77345,26436,839001131823
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,572
17,869
24,375
24,098
20,565
24,132
21,280
19,861
11,194
16,409
18,257
19,201
18,489
12,077
7,173
9,300
10,813
4,881
4,340
448
4,467
5,862
450
29,747
35,672
34,145
41,667
36,266
32,414
31,859
29,381
24,100
20,775
19,775
17,264
17,26419,77520,77524,10029,38131,85932,41436,26641,66734,14535,67229,7474505,8624,4674484,3404,88110,8139,3007,17312,07718,48919,20118,25716,40911,19419,86121,28024,13220,56524,09824,37517,8695,57200000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
99
147
145
160
105
115
39
36
13
9
3,343
3,614
47
30
39
16
16
11
17
9
8
11
0
136
233
159
247
120
80
620
660
618
604
172
52
521726046186606208012024715923313601189171116163930473,6143,34391336391151051601451479900000000000000
       Other Current Assets 
10
10
0
0
91
0
123
252
770
256
1,273
286
230
186
181
348
350
269
154
457
330
262
89
453
408
248
5,113
5,728
5,520
5,411
5,149
5,755
5,546
5,373
5,147
5,916
5,661
458
283
1,544
43,429
1,378
604
1,275
945
1,127
691
594
773
7735946911,1279451,2756041,37843,4291,5442834585,6615,9165,1475,3735,5465,7555,1495,4115,5205,7285,113248408453892623304571542693503481811862302861,273256770252123091001010
   > Long-term Assets 
0
0
0
0
0
0
0
80
74
73
48
64
98
106
9,647
6,139
500
132
151
142
134
127
120
113
106
56
52
47
43
39
35
31
27
27
26
25
24
4,633
24
24
6,103
4,106
4,114
3,314
3,408
3,407
3,399
139
140
1401393,3993,4073,4083,3144,1144,1066,10324244,6332425262727313539434752561061131201271341421511325006,1399,6471069864487374800000000
       Property Plant Equipment 
79
0
0
0
49
0
40
35
29
28
25
41
74
83
80
83
76
108
120
112
103
96
89
82
75
32
28
23
19
15
11
7
4
3
2
1
0
0
0
0
7
32
40
37
132
131
123
115
116
116115123131132374032700001234711151923283275828996103112120108768380837441252829354004900079
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
400
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,609
0
0
2,022
0
0
0
0
0
0
0
0
000000002,022004,609000000000000000000004000000000000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
45
45
45
24
24
24
24
24
24
24
24
31
31
31
31
31
31
31
24
24
24
24
24
24
24
24
24
24
24
24
24
24
24
4,074
4,074
4,074
24
24
24
24
24
24
2424242424244,0744,0744,0742424242424242424242424242424243131313131313124242424242424244545450000000
> Total Liabilities 
8
7
4
7
12
15
18
1,628
1,284
1,500
1,670
2,057
1,634
1,337
1,665
2,179
3,392
2,994
2,585
1,572
1,326
2,345
2,900
2,484
6,345
15,008
11,423
10,923
11,418
10,437
9,827
9,837
13,370
14,439
10,400
10,243
10,011
8,186
11,434
7,578
6,912
5,194
2,304
1,775
1,908
2,062
1,931
2,271
2,632
2,6322,2711,9312,0621,9081,7752,3045,1946,9127,57811,4348,18610,01110,24310,40014,43913,3709,8379,82710,43711,41810,92311,42315,0086,3452,4842,9002,3451,3261,5722,5852,9943,3922,1791,6651,3371,6342,0571,6701,5001,2841,6281815127478
   > Total Current Liabilities 
8
7
4
7
12
15
18
1,628
1,284
1,500
1,670
2,057
1,634
1,337
1,665
2,179
3,392
2,994
2,585
1,572
1,326
2,345
2,900
2,484
6,345
6,284
2,843
3,070
4,492
4,277
4,443
5,235
4,965
4,060
4,232
5,789
6,584
5,397
8,808
6,433
5,617
3,520
1,713
1,511
1,678
1,930
1,827
2,241
2,632
2,6322,2411,8271,9301,6781,5111,7133,5205,6176,4338,8085,3976,5845,7894,2324,0604,9655,2354,4434,2774,4923,0702,8436,2846,3452,4842,9002,3451,3261,5722,5852,9943,3922,1791,6651,3371,6342,0571,6701,5001,2841,6281815127478
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,341
1,549
2,341
3,333
3,333
3,333
3,333
3,333
1,667
2,332
3,206
3,333
3,333
3,958
3,136
2,311
1,482
0
0
0
0
0
0
17
170000001,4822,3113,1363,9583,3333,3333,2062,3321,6673,3333,3333,3333,3333,3332,3411,5491,3410000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,341
1,549
2,341
3,333
3,333
3,333
3,333
3,333
1,667
2,332
3,206
3,333
3,333
3,958
3,136
2,311
1,482
0
0
0
0
0
0
0
00000001,4822,3113,1363,9583,3333,3333,2062,3321,6673,3333,3333,3333,3333,3332,3411,5491,3410000000000000000000000000
       Accounts payable 
147
7
4
7
12
15
17
1,483
1,027
773
642
399
306
380
399
457
507
1,077
989
865
246
854
1,114
804
598
388
407
240
671
518
116
1,360
1,182
1,655
907
1,048
1,597
558
906
726
1,289
470
814
630
600
796
518
1,101
1,396
1,3961,1015187966006308144701,2897269065581,5971,0489071,6551,1821,3601165186712404073885988041,1148542468659891,0775074573993803063996427731,0271,483171512747147
       Other Current Liabilities 
8
0
0
0
0
0
0
145
257
727
1,029
1,658
1,327
958
1,266
1,722
2,885
1,917
1,596
707
1,080
1,491
1,786
1,680
5,747
4,555
887
489
487
426
993
541
449
738
993
1,534
1,653
1,505
2,500
1,000
1,000
1,568
899
881
1,078
1,134
1,310
1,140
1,218
1,2181,1401,3101,1341,0788818991,5681,0001,0002,5001,5051,6531,5349937384495419934264874898874,5555,7471,6801,7861,4911,0807071,5961,9172,8851,7221,2669581,3271,6581,0297272571450000008
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
-3
0
0
0
-3
0
0
0
0
0
0
0
0
0
0
0
0
8,724
8,580
7,854
6,927
6,160
5,384
4,602
8,406
10,379
6,169
4,455
3,427
2,789
2,625
1,145
1,296
1,674
590
264
230
132
104
29
0
0291041322302645901,6741,2961,1452,6252,7893,4274,4556,16910,3798,4064,6025,3846,1606,9277,8548,5808,724000000000000-3000-300000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,580
7,854
6,927
6,160
5,384
4,602
3,814
4,688
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000004,6883,8144,6025,3846,1606,9277,8548,58000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,500
500
1,296
500
0
0
0
132
0
0
0
0001320005001,2965001,50000000000000000000000000000000000000000
> Total Stockholder Equity
25
20
-1
-6
-11
-15
-18
35,542
44,824
40,602
33,815
29,961
26,360
23,720
52,132
46,249
41,985
35,780
30,763
27,982
26,017
24,877
25,148
23,771
18,980
16,672
13,879
11,762
9,434
12,552
9,850
7,505
6,288
6,553
13,085
14,508
15,342
42,391
35,746
32,811
45,570
42,410
39,890
37,649
35,635
31,960
28,552
22,482
20,369
20,36922,48228,55231,96035,63537,64939,89042,41045,57032,81135,74642,39115,34214,50813,0856,5536,2887,5059,85012,5529,43411,76213,87916,67218,98023,77125,14824,87726,01727,98230,76335,78041,98546,24952,13223,72026,36029,96133,81540,60244,82435,542-18-15-11-6-12025
   Common Stock
0
0
0
0
0
0
0
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
4
5
6
7
7
9
9
9
9
9
9
9
9
9
9
9
9
9999999999997765432222222222222222211111110000000
   Retained Earnings -199,777-197,495-190,844-187,295-183,425-181,195-178,786-176,154-172,666-185,290-182,209-175,400-172,032-167,521-163,207-156,838-151,067-147,775-144,715-141,284-138,060-134,834-132,375-129,120-126,400-121,068-116,368-110,278-105,417-102,450-99,215-93,455-86,445-81,812-75,439-71,193-68,237-64,197-60,103-53,132-47,864-43,474-88-85-82-77-71-10-5
   Capital Surplus 
0
30
70
70
70
70
70
79,015
92,687
93,732
93,958
94,198
94,636
94,952
127,620
128,094
128,503
129,270
130,011
130,471
131,481
135,200
141,555
144,878
145,423
145,850
146,304
146,639
147,533
153,873
154,600
155,318
157,392
163,427
176,327
182,063
187,408
217,845
217,987
0
218,286
0
0
0
0
219,284
0
0
0
000219,2840000218,2860217,987217,845187,408182,063176,327163,427157,392155,318154,600153,873147,533146,639146,304145,850145,423144,878141,555135,200131,481130,471130,011129,270128,503128,094127,62094,95294,63694,19893,95893,73292,68779,0157070707070300
   Treasury Stock000-410000-410-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41-41000-53000000
   Other Stockholders Equity 
30
30
70
70
70
70
70
80,029
93,706
94,755
94,943
95,186
95,630
95,950
127,579
128,053
128,462
129,230
129,970
130,430
131,440
135,159
141,514
144,838
145,382
145,810
146,264
146,598
147,492
153,832
154,560
155,278
157,351
163,386
176,286
182,022
187,367
217,805
217,946
218,096
218,246
218,623
218,752
218,912
219,071
219,243
219,403
219,982
220,131
220,131219,982219,403219,243219,071218,912218,752218,623218,246218,096217,946217,805187,367182,022176,286163,386157,351155,278154,560153,832147,492146,598146,264145,810145,382144,838141,514135,159131,440130,430129,970129,230128,462128,053127,57995,95095,63095,18694,94394,75593,70680,02970707070703030



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue110
Cost of Revenue-29
Gross Profit8181
 
Operating Income (+$)
Gross Profit81
Operating Expense-15,051
Operating Income-14,970-14,970
 
Operating Expense (+$)
Research Development10,147
Selling General Administrative4,905
Selling And Marketing Expenses0
Operating Expense15,05115,051
 
Net Interest Income (+$)
Interest Income1,365
Interest Expense-0
Other Finance Cost-0
Net Interest Income1,365
 
Pretax Income (+$)
Operating Income-14,970
Net Interest Income1,365
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-16,351-13,589
EBIT - interestExpense = -14,970
-16,351
-16,352
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-14,970-16,351
Earnings Before Interest and Taxes (EBITDA)-14,941
 
After tax Income (+$)
Income Before Tax-16,351
Tax Provision-1
Net Income From Continuing Ops-16,300-16,352
Net Income-16,352
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses15,080
Total Other Income/Expenses Net-1,381-1,365
 

Technical Analysis of Lipocine
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lipocine. The general trend of Lipocine is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lipocine's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lipocine Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 5.21 < 5.26 < 5.3873.

The bearish price targets are: 4 > 3.2 > 3.18.

Tweet this
Lipocine Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lipocine Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lipocine Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lipocine Inc. The current macd is 0.23741384.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lipocine price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Lipocine. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Lipocine price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Lipocine Inc Daily Moving Average Convergence/Divergence (MACD) ChartLipocine Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lipocine Inc. The current adx is 25.65.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Lipocine shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Lipocine Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lipocine Inc. The current sar is 3.8033.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Lipocine Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lipocine Inc. The current rsi is 71.29. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Lipocine Inc Daily Relative Strength Index (RSI) ChartLipocine Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lipocine Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lipocine price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Lipocine Inc Daily Stochastic Oscillator ChartLipocine Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lipocine Inc. The current cci is 166.54.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Lipocine Inc Daily Commodity Channel Index (CCI) ChartLipocine Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lipocine Inc. The current cmo is 49.98.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Lipocine Inc Daily Chande Momentum Oscillator (CMO) ChartLipocine Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lipocine Inc. The current willr is -8.60301508.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Lipocine Inc Daily Williams %R ChartLipocine Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lipocine Inc.

Lipocine Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lipocine Inc. The current atr is 0.39943086.

Lipocine Inc Daily Average True Range (ATR) ChartLipocine Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lipocine Inc. The current obv is 8,366,120.

Lipocine Inc Daily On-Balance Volume (OBV) ChartLipocine Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lipocine Inc. The current mfi is 79.69.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Lipocine Inc Daily Money Flow Index (MFI) ChartLipocine Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lipocine Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-16MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Lipocine Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lipocine Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5071.290
Ma 20Greater thanMa 504.153
Ma 50Greater thanMa 1004.015
Ma 100Greater thanMa 2003.373
OpenGreater thanClose4.950
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Lipocine with someone you think should read this too:
  • Are you bullish or bearish on Lipocine? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lipocine? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lipocine Inc

I send you an email if I find something interesting about Lipocine Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Lipocine Inc.

Receive notifications about Lipocine Inc in your mailbox!